Therapeutic Indications

Ambrisentan is indicated for:

Pulmonary arterial hypertension (PAH) classified as WHO functional class II and III

Irrespective of gender only Adults (18 years old or older)

Ambrisentan is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 5-10 mg once daily

Contraindications

Active ingredient Ambrisentan is contraindicated in the following cases:

Severe hepatic impairment

No gender/age discrimination

Ambrisentan is contraindicated in severe hepatic impairment.

Idiopathic pulmonary fibrosis

No gender/age discrimination

Ambrisentan is contraindicated in idiopathic pulmonary fibrosis.

Lactation

No gender/age discrimination

It is not known whether ambrisentan is excreted in human breast milk. The excretion of ambrisentan in milk has not been studied in animals. Therefore breast-feeding is contraindicated in patients taking ambrisentan.

Pregnancy

No gender/age discrimination

Ambrisentan is contraindicated in pregnancy. Animal studies have shown that ambrisentan is teratogenic. There is no experience in humans. Women receiving ambrisentan must be advised of the risk of foetal harm and alternative therapy initiated if pregnancy occurs.